UBS Initiates Coverage On Ocular Therapeutix with Buy Rating, Announces Price Target of $14

Benzinga Newsdesk www.benzinga.com Neutral 56.5%

Neg 0% Neu 56.5% Pos 0%

UBS analyst Alice Nettleton initiates coverage on Ocular Therapeutix (NASDAQ:OCUL) with a Buy rating and announces Price Target of $14.